External validation of a multiple sclerosis treatment decision score using data from the ProVal-MS cohort study.
Buchka S, Hapfelmeier A, Kirschke JS, Steuerwald V, Naumann M, Soto-Rey I, Rohr SO, Kramer F, Behrens L, Oswald E, Kümpfel T, Zimmermann H, Hoffmann VS, Hagedorn M, Albashiti F, Krumbholz M, Ziemann U, Kohlbacher O, Sailer B, Braunmüller V, Biergans S, de Arruda Botelho Herr M, Ernemann U, Bürkle E, Bender B, Daul A, Ruff C, Römhild J, Wiestler B, Sepp D, Spengler H, Pallaoro P, Boeker M, Kohlmayer F, Dehmelt V, Berthele A, Mühlau M, Uibel P, Wauschkuhn J, Kuhn K, Senel M, Vardakas I, Taranu D, Kestler HA, Sollmann N, Irmak Ön B, Bilger S, Mansmann U, Bayas A, Havla J, Kowarik MC, Tumani H, Hemmer B; ProVal-MS Study Group.
Buchka S, et al. Among authors: ernemann u.
Ther Adv Neurol Disord. 2025 Nov 21;18:17562864251391095. doi: 10.1177/17562864251391095. eCollection 2025.
Ther Adv Neurol Disord. 2025.
PMID: 41281704
Free PMC article.